$NBY News

Last published 7mo ago

7mo agoNBY SDEVNovaBay Pharmaceuticals Announces Name Change to Stablecoin Development Corporation, Reports Initial Staking Rewards, and Provides SKY Token Holdings UpdateGlobeNewswireFollowing $134 million investment from R01 Fund LP, Framework Ventures, Tether Investments, S.A. de C.V., and Sky Frontier Foundation, Stablecoin Development Corporation has acquired 2.06 billion SKY tokens
1y agoNBYNovaBay Pharmaceuticals, Inc. Regains Compliance with NYSE American Continued Listing StandardsGlobeNewswireEMERYVILLE, Calif., Oct. 20, 2025 (GLOBE NEWSWIRE) -- NovaBay Pharmaceuticals, Inc. (NYSE:NBY) ("NovaBay" or the "Company") announces that it has regained compliance with the NYSE American's continued
1y agoNBYNovaBay Pharmaceuticals Issues a Reminder of Important Information Regarding the Pending Special Dividend and Upcoming 2025 Annual MeetingGlobeNewswireEMERYVILLE, Calif., Sept. 18, 2025 (GLOBE NEWSWIRE) -- NovaBay® Pharmaceuticals, Inc. (NYSE:NBY) (the "Company") previously announced a one-time special cash dividend of $0.80 per share for the Company's common
1y agoNBYNovaBay Pharmaceuticals Announces One-Time Special Cash Dividend of $0.80 Per ShareGlobeNewswireEMERYVILLE, Calif., Aug. 26, 2025 (GLOBE NEWSWIRE) -- NovaBay® Pharmaceuticals, Inc. (NYSE:NBY) ("NovaBay" or the "Company") announces its Board of Directors and the Special Transaction Committee of the Board of
1y agoNBYNovaBay Pharmaceuticals Enters Into $6 Million Securities Purchase Agreement with Investor David E. LazarGlobeNewswireEMERYVILLE, Calif., Aug. 19, 2025 (GLOBE NEWSWIRE) -- NovaBay® Pharmaceuticals, Inc. (NYSE:NBY) ("NovaBay" or the "Company") announces it has entered into a $6 million securities purchase agreement with private
1y agoNBYNovaBay Pharmaceuticals to Hold Special Meeting of StockholdersBusiness WireStockholders as of the March 18, 2025 record date will be entitled to vote Company engages financial advisor to explore strategic options should stockholders fail to approve the dissolution proposal NovaBay®
1y agoNBYNovaBay Pharmaceuticals Completes the Sale of its Eyecare Business to PRN and Further Adjourns its Special Meeting of Stockholders on Dissolution ProposalBusiness WireStockholders voted to unlock the value of NovaBay's Avenova® eyecare business by approving the $11.5 million asset sale Reconvened Special Meeting adjourned to allow additional time for votes to reach the 50%
1y agoNBYNovaBay Pharmaceuticals Announces the Further Adjournment of the Special Meeting of StockholdersBusiness WireReconvened meeting adjourned due to insufficient votes to reach the 50% threshold of outstanding common shares voting in favor of Proposal One and Proposal Two Stockholders who have not voted are strongly encouraged
1y agoNBYNovaBay CEO Letter to Stockholders Urges a FOR Vote at Upcoming Reconvened Special MeetingBusiness WireStockholders are urged to vote FOR Proposal One and Proposal Two before the reconvened Special Meeting scheduled for December 18 NovaBay® Pharmaceuticals, Inc. (NYSE:NBY) ("NovaBay" or the "Company") announces
1y agoNBYNovaBay Pharmaceuticals to Reconvene Special Meeting of Stockholders on December 18, 2024Business WireInitial meeting adjourned due to insufficient votes to reach the 50% threshold of outstanding common shares voting in favor of Proposal One and Proposal Two Stockholders who have not voted are strongly encouraged to
1y agoNBYProminent Independent Proxy Advisory Firm ISS Supports NovaBay Pharmaceuticals' Proposals to Authorize the Sale of its Avenova BrandBusiness WireNovaBay urges stockholders to vote FOR all proxy proposals at the Special Meeting of Stockholders NovaBay® Pharmaceuticals, Inc. (NYSE:NBY) ("NovaBay" or the "Company") announces that the largest institutional
2y agoNBYNovaBay Pharmaceuticals Accepts Revised Offer from PRN Physician Recommended Nutriceuticals, LLC and Enters into an Amendment to the Asset Purchase Agreement to Increase Purchase PriceBusiness WireNovaBay® Pharmaceuticals, Inc. (NYSE:NBY) ("NovaBay" or the "Company") today announces that the Company has accepted a revised transaction proposal from PRN Physician Recommended Nutriceuticals, LLC ("PRN") to
2y agoNBYNovaBay Pharmaceuticals Board Determines Unsolicited Offer is Superior to Asset Purchase Agreement with PRN Physician Recommended Nutriceuticals, LLCBusiness WireNovaBay® Pharmaceuticals, Inc. (NYSE:NBY) ("NovaBay" or the "Company") announces that the Company's board of directors has determined that an unsolicited and non-binding offer from Refresh Acquisitions BidCo LLC
2y agoCOFS ARC RFL NBYKuehn Law Encourages COFS, ARC, RFL, and NBY Investors to Contact Law FirmPR NewswireKuehn Law, PLLC, a shareholder litigation law firm, is investigating potential claims related to the below-listed proposed mergers. Kuehn Law may...
2y agoNBYAcumen Health Holdings ("Acumen") to Acquire the Avenova brand from NovaBay PharmaceuticalsPR NewswireAcumen Health Holdings, LLC, a professionally recommended, consumer-preferred dietary supplements company focused on eye health and companion...
2y agoNBYNovaBay Pharmaceuticals Signs Definitive Agreement to Sell its Avenova AssetsBusiness WireNovaBay® Pharmaceuticals, Inc. (NYSE:NBY) ("NovaBay" or the "Company") announces it has entered into a definitive asset purchase agreement (the "Agreement") with PRN Physician Recommended Nutriceuticals, LLC
2y agoNBYNovaBay Pharmaceuticals, Inc. (NBY) Q2 2024 Earnings Call TranscriptEarnings Call Transcripts
2y agoNBYNovaBay Pharmaceuticals Reports Second Quarter 2024 Financial ResultsBusiness WireEyecare product revenue increased 8% driven by higher sales of Avenova®-branded products through online channels Sales and marketing expenses declined 13% reflecting efficient growth through digital marketing
2y agoNBYNovaBay Pharmaceuticals to Hold Second Quarter 2024 Conference Call on August 13, 2024Business WireNovaBay® Pharmaceuticals, Inc. (NYSE:NBY) announces that it will report financial results for the three and six months ended June 30, 2024 after market close on Tuesday, August 13, 2024 and will hold an investment
2y agoNBYNovaBay Pharmaceuticals Reports Record Amazon Prime Day SalesBusiness WireNovaBay Pharmaceuticals, Inc. (NYSE:NBY) reports record sales of Avenova®-branded eyecare products during the Amazon Prime Day event, which was held July 16-17, 2024. Over the two-day period, Avenova sales were 17%
2y agoNBYNovaBay Pharmaceuticals Announces Closing of $3.87 Million Underwritten Public Offering, Including Partial Exercise of Overallotment OptionBusiness WireNovaBay Pharmaceuticals, Inc. (NYSE:NBY) (the "Company" or "NovaBay") today announced the closing of its previously announced underwritten public offering of common stock, pre-funded warrants, Series F-1 warrants,
2y agoNBYNovaBay Pharmaceuticals Announces Pricing of $3.5 Million Underwritten Public OfferingBusiness WireNovaBay Pharmaceuticals, Inc. (NYSE:NBY) (the "Company" or "NovaBay"), today announced the pricing of its underwritten public offering of 3,200,380 shares of common stock (or pre-funded warrants in lieu thereof),
2y agoNBYNovaBay Pharmaceuticals Offers 20% Discounts on Avenova Eyecare Products During Amazon Prime DayBusiness WireNovaBay Pharmaceuticals, Inc. (NYSE:NBY) announces 20% discounts on Avenova®-branded eyecare products and product bundles during Amazon Prime Day being held July 16-17, 2024. "Prime Day has been a highly
2y agoNBYNovaBay Pharmaceuticals Reports Preliminary Second Quarter 2024 Net Revenue of $2.4 MillionBusiness WireEyecare revenue for both the second quarter and the first half of 2024 increased by 9% over the comparable prior-year periods, driven by higher online sales The number of Avenova® subscribers on Amazon increased
2y agoEYEN NBYNovaBay Pharmaceuticals and Eyenovia Commence Co-Promotion ActivitiesBusiness WirePartnership co-promoting NovaBay's Avenova® Antimicrobial Lid & Lash Solution to large ophthalmic surgery centers along with one of Eyenovia's FDA-approved product MydCombi™ Preparing for
2y agoNBYNovaBay Pharmaceuticals Supports National Dry Eye Awareness Month with Multiple Avenova Product PromotionsBusiness WireNovaBay Pharmaceuticals, Inc. (NYSE:NBY) announces it will be offering special promotions and discounts on its Avenova®-branded eyecare products to customers and eyecare professionals throughout July in support of
2y agoNBYNovaBay Pharmaceuticals Plan of Compliance Accepted by the NYSE AmericanBusiness WireNovaBay® Pharmaceuticals, Inc. (NYSE:NBY) (the "Company") announces that the NYSE American LLC ("NYSE American") has accepted the Company's plan to regain compliance with NYSE American's continued listing
2y agoNBYNovaBay Pharmaceuticals Announces Approval of All Proposals at its 2024 Annual Meeting of Stockholders and Provides Other Corporate UpdatesBusiness WireAnnounces a 1-for-35 Reverse Stock Split and Receipt of NYSE American Notice Regarding Stockholders' Equity NovaBay® Pharmaceuticals, Inc. the "Company") (NYSE:NBY) announces that a quorum was reached and that
2y agoNBYNovaBay Pharmaceuticals Launches Avenova Product Bundles for Individualized Relief from Multifactorial Dry Eye SymptomsBusiness WireApproximately 16 million Americans suffer from dry eye disease with the U.S. market for dry eye treatment projected to reach $4.86 billion by 2030 NovaBay® Pharmaceuticals, Inc. (NYSE:NBY), a company developing
2y agoNBYNovaBay Pharmaceuticals, Inc. (NBY) Q1 2024 Earnings Call TranscriptEarnings Call Transcripts
2y agoNBYNovaBay Pharmaceuticals Reports First Quarter 2024 Financial ResultsBusiness WireNet product sales increased 13% over the prior year driven by higher sales of Avenova®-branded products through OTC channels and branded wound care products Sales and marketing expenses declined 15% reflecting
2y agoNBYNovaBay Pharmaceuticals Announces Record Ordered Product Sales of Avenova-Branded Products in April through AmazonBusiness WireOrdered product sales of Avenova®-branded products on Amazon.com set back-to-back records in March and April 2024 Enhanced marketing program provides potential for additional growth in the U.S. dry eye disease
2y agoNBYNovaBay Pharmaceuticals to Hold 2024 First Quarter Conference Call on May 9, 2024Business WireNovaBay® Pharmaceuticals, Inc. (NYSE:NBY) announces that it will report financial results for the three months ended March 31, 2024 after market close on Thursday, May 9, 2024 and will hold an investment community
2y agoNBYNovaBay Pharmaceuticals Announces New and Enhanced Direct-to-Consumer Marketing to Efficiently Engage Customers and Drive Avenova SalesBusiness WireNovaBay® Pharmaceuticals, Inc. (NYSE:NBY), a company developing and commercializing high-quality eyecare and wound care products, announces a new and enhanced marketing program that includes text message
2y agoNBYNovaBay Pharmaceuticals Reports Preliminary Eyecare and Wound Care Revenue Increased 13% for the First Quarter of 2024 on Lower Sales and Marketing ExpensesBusiness WireGrowth driven by efficient Avenova® direct-to-consumer e-marketing programs NovaBay® Pharmaceuticals, Inc. (NYSE:NBY) reports preliminary net revenue for its eyecare and wound care business for the first
2y agoNBYNovaBay Pharmaceuticals Reports 2023 Fourth Quarter and Full Year Financial ResultsBusiness WireQ4 net sales from the eyecare and wound care segment grew 10% over the prior year with higher sales from the Avenova® physician dispensed and OTC channels, and from branded wound care products Sales and
2y agoNBYNovaBay Pharmaceuticals to Hold 2023 Fourth Quarter and Full Year Conference Call on March 26, 2024Business WireNovaBay® Pharmaceuticals, Inc. (NYSE:NBY) announces that it will report financial results for the three and 12 months ended December 31, 2023 after market close on Tuesday, March 26, 2024 and will hold an
2y agoNBYNovaBay Pharmaceuticals Announces Agreement to Sell its DERMAdoctor Skincare Business Segment; Announces Preliminary Financial Results for Fourth Quarter and Year Ended December 31, 2023Business WireDERMAdoctor sale reduces operating expenses and bolsters cash NovaBay® Pharmaceuticals, Inc. (NYSE:NBY), a company developing and commercializing high-quality eyecare and wound care products, announces that the
2y agoEYEN NBYNovaBay Pharmaceuticals and Eyenovia to Co-Promote Prescription Ophthalmic Products to U.S. Eyecare ProfessionalsGlobeNewswireEMERYVILLE, Calif. and NEW YORK, March 13, 2024 (GLOBE NEWSWIRE) -- NovaBay Pharmaceuticals, Inc. (NYSE:NBY) and Eyenovia, Inc. (NASDAQ:EYEN) announced the signing of a co-promotion agreement to commercialize
2y agoNBYNovaBay Pharmaceuticals Reports 64% Year-Over-Year Growth in Avenova Unit Subscription-Based SalesBusiness WireNovaBay Pharmaceuticals, Inc. (NYSE:NBY) announces a 64% increase in online subscription-based unit sales for its Avenova® Lid & Lash Spray Solution and a 38% increase in subscription-based customers in 2023
2y agoNBY SNOANovaBay Pharmaceuticals and Sonoma Pharmaceuticals Agree to Market Avenova-branded Products in the European Union Through Sonoma's Extensive Distributor NetworkBusiness WireNovaBay Pharmaceuticals, Inc. (NYSE:NBY) and Sonoma Pharmaceuticals, Inc. (NASDAQ:SNOA) today announced an agreement for the sale and marketing of Avenova®-branded products by Sonoma in the European Union. The new
2y agoNBY SNOANovaBay Pharmaceuticals and Sonoma Pharmaceuticals Agree to Market Avenova-branded Products in the European Union Through Sonoma's Extensive Distributor NetworkACCESS NewswireEMERYVILLE, CA and BOULDER, CO / ACCESSWIRE / January 9, 2024 / NovaBay Pharmaceuticals, Inc. and Sonoma Pharmaceuticals, Inc. today announced an agreement for the sale and marketing of
2y agoNBYNovaBay Pharmaceuticals Partners with Woo University to Educate Eyecare Professionals on the Use of Amniotic MembranesBusiness WireNovaBay Pharmaceuticals, Inc. (NYSE:NBY) announces its partnership with Woo University to support the education of eyecare professionals on the use of amniotic membranes. A free webinar is being held Thursday, December
3y agoNBYNovaBay Pharmaceuticals, Inc. (NBY) Q3 2023 Earnings Call TranscriptEarnings Call Transcripts
3y agoNBYNovaBay Pharmaceuticals Reports Third Quarter 2023 Financial ResultsBusiness WireNet product revenue from Avenova®-branded eyecare products grew 7% year-over-year, reflecting an increased contribution from the physician dispensed channel Sales and marketing expenses declined 7% versus the
3y agoNBYNovaBay Pharmaceuticals to Hold Third Quarter 2023 Conference Call on November 9, 2023Business WireNovaBay® Pharmaceuticals, Inc. (NYSE:NBY) announces that it will report financial results for the three and nine months ended September 30, 2023 after market close on Thursday, November 9, 2023 and will hold an
3y agoNBYNovaBay Pharmaceuticals Expands Physician Dispensed Sales Channel with New Avenova ProgramsBusiness WireNovaBay® Pharmaceuticals, Inc. (NYSE:NBY), a company developing and commercializing high-quality eyecare, skincare and wound care products, announces the launch of two new promotional programs for ophthalmologists
3y agoNBYNovaBay Pharmaceuticals to Present at the Dawson James Small Cap Growth ConferenceBusiness WireNovaBay Pharmaceuticals, Inc. (NYSE:NBY), a company developing and commercializing high-quality eyecare, skincare and wound care products, announces that Justin Hall, CEO and General Counsel, will present a company
3y agoNBYNovaBay Pharmaceuticals Reports Second Quarter 2023 Financial ResultsBusiness WireNet product revenue of $4.6 million increased 26% over the prior-year quarter Wound care sales of $1.3 million mark a record quarterly high Sales and marketing expenses reduced by 16% through optimized digital
3y agoNBYNovaBay Pharmaceuticals to Hold Second Quarter 2023 Conference Call on August 10, 2023Business WireNovaBay® Pharmaceuticals, Inc. (NYSE:NBY) announces that it will report financial results for the three and six months ended June 30, 2023 after market close on Thursday, August 10, 2023 and will hold an investment